This trial is active, not recruiting.

Condition heart failure
Treatment lidocaine
Sponsor First Affiliated Hospital of Harbin Medical University
Start date June 2014
End date December 2015
Trial size 100 participants
Trial identifier NCT02391142, CSB-CHF


The purpose of this study is to evaluate the effect of Cardiac Sympathetic Blockade on Mortality, re-hospitalization rate, symptoms, quality of life, exercise tolerance, cardiac structure, systolic function, electrical activities and concentration of B - type natriuretic peptide precursor in patients with Chronic Heart Failure.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
lidocaine or ropivacaine epidural injection
lidocaine ropivacaine
0.5% lidocaine 5ml epidural injection every 2 hours per day or 0.2% ropivacaine 5ml epidural injection every 4 hours per day, last for 4weeks

Primary Outcomes

All cause mortality
time frame: one year

Secondary Outcomes

Rehospitalization rate
time frame: one year

Eligibility Criteria

Male or female participants from 20 years up to 70 years old.

Inclusion Criteria: - 20-70 years old - more than 3 months of chronic heart failure history or clinical symptoms of heart failure last for more than 3 months (including acute episode of chronic heart failure), chronic heart failure diagnostic criteria refer to 2012ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - NYHA functional class III-IV, ejection fraction ≤45% - NT-proBNP>400ng/L Exclusion Criteria: - first episode of acute heart failure - unrepaired valvular heart disease accompanied with Hemodynamic changes - hypertrophic cardiomyopathy, pericardial disease, congenital heart disease, severe pulmonary hypertension - Second-degree type 2 or worse sinoatrial or atrioventricular block without pacemaker therapy - right heart failure caused by various diseases, respiratory failure or right heart failure induced by chronic obstructive pulmonary disease - overt renal decompensation: serum creatinine>2.1mg/dl(186umol/L) - severe hepatic dysfunction, transaminase or alkaline phosphatase > 3 times the upper limit of normal - Cerebral vascular accident in three months( cerebral infarction, cerebral embolism, cerebral hemorrhage,etc) - life expectancy shorter than 6 months - patients with a previous or present history of tumour or precancerous lesions confirmed by pathological examination - Spine Deformity or skin infection at puncture site - participate in any clinical drug trials in the three months - the patients who do not sign the informed consent, unable or unwilling to comply with the requirements of the protocol or unsuitable for the study

Additional Information

Official title Clinical Assessment of the Treatment With Cardiac Sympathetic Blockade on Chronic Heart Failure
Trial information was received from ClinicalTrials.gov and was last updated in March 2015.
Information provided to ClinicalTrials.gov by First Affiliated Hospital of Harbin Medical University.